Associated Papers
MSH2, MSH6, MLH1, and PMS2 immunohistochemistry as highly sensitive screening method for DNA mismatch repair deficiency syndromes in pediatric high-grade glioma.
Friker LL et al.
Acta Neuropathologica, 2025
39894875 (PubMed )
Supplement: 401_2025_2846_MOESM1_ESM.xlsx › Sheet1
ASXL1 inactivation and reduced H3K27me3 across central nervous system tumors.
Zhang KY et al.
Acta Neuropathologica, 2024
39141113 (PubMed )
Supplement: 401_2024_2785_MOESM2_ESM.xlsx › STab2
Application of Genomic Sequencing to Refine Patient Stratification for Adjuvant Therapy in Renal Cell Carcinoma.
Vasudev NS et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2023
36815791 (PubMed )
Supplement: ccr-22-1936_supplementary_table_s2_suppts2.xlsx › Sheet1
Somatic Mutations Alter Interleukin Signaling Pathways in Grade II Invasive Breast Cancer Patients: An Egyptian Experience.
Nassar A et al.
Current Issues in Molecular Biology, 2022
36547062 (PubMed )
Supplement: cimb-44-00401-s001.zip › supplementary_2.xlsx › cancer_driver
Importance of Early Next-Generation Sequencing in Microsatellite Unstable Colon Cancer With a High Tumor Mutation Burden.
Ashish S et al.
Cureus, 2022
Metastatic and recurrent adrenocortical cancer is not defined by its genomic landscape.
Fojo T et al.
Bmc Medical Genomics, 2020
33148256 (PubMed )
Supplement: 12920_2020_809_MOESM2_ESM.xlsx › Supplemental_Table_1__part_1_
Molecular characterisation of metanephric adenomas beyond BRAF: genetic evidence for potential malignant evolution.
Chan E et al.
Histopathology, 2020
Select a paper to view details